Ovarian Endometrioid Adenocarcinoma Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01010126Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerTreatment